{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:00:35Z","timestamp":1792130435705,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"NEI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["EY01792"],"award-info":[{"award-number":["EY01792"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.oret.2025.01.017","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T19:03:19Z","timestamp":1738695799000},"page":"655-666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE\/RHINE Trials in Diabetic Macular Edema"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7791-6998","authenticated-orcid":false,"given":"Jennifer I.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel J.","family":"Amador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilsher S.","family":"Dhoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avni","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Fraser-Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwatobi O.","family":"Idowu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul N.","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florie A.","family":"Mar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pollreisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Rachitskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio G.","family":"Schlottmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Y.Y.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2025.01.017_bib1","doi-asserted-by":"crossref","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic Retinopathy Preferred Practice Pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.017_bib2","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study","volume":"9","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.oret.2025.01.017_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.preteyeres.2017.10.006","article-title":"Mechanisms of macular edema: beyond the surface","volume":"63","author":"Daruich","year":"2018","journal-title":"Prog Retin Eye Res"},{"issue":"10 suppl","key":"10.1016\/j.oret.2025.01.017_bib4","first-page":"s284","article-title":"Overview of diabetic macular edema","volume":"22","author":"Holekamp","year":"2016","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.oret.2025.01.017_bib5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2025.01.017_bib6","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.oret.2025.01.017_bib7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","article-title":"Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study)","volume":"127","author":"Glassman","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.017_bib8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.017_bib9","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.2147\/OPTH.S281501","article-title":"Real-world outcomes in patients with diabetic macular edema treated long term with ranibizumab (VISION study)","volume":"14","author":"Van Aken","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.017_bib10","article-title":"Diabetic retinopathy","volume":"2","author":"Wong","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.oret.2025.01.017_bib11","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI58832","article-title":"Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling","volume":"122","author":"Felcht","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.oret.2025.01.017_bib12","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1038\/ncomms6962","article-title":"Endothelial destabilization by angiopoietin-2 via integrin beta1 activation","volume":"6","author":"Hakanpaa","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.oret.2025.01.017_bib13","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.2337\/db13-1942","article-title":"Angiopoietin 2 induces pericyte apoptosis via \u03b13\u03b21 integrin signaling in diabetic retinopathy","volume":"63","author":"Park","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.oret.2025.01.017_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.347","article-title":"Angiopoietin 2 induces astrocyte apoptosis via \u03b1v\u03b25-integrin signaling in diabetic retinopathy","volume":"7","author":"Yun","year":"2016","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.oret.2025.01.017_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nm1351","article-title":"Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation","volume":"12","author":"Fiedler","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.oret.2025.01.017_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000003003","article-title":"The angiopoietin\/Tie pathway in retinal vascular diseases: a review","volume":"41","author":"Heier","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.01.017_bib17","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.01.017_bib18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrd.2016.278","article-title":"Therapeutic targeting of the angiopoietin-TIE pathway","volume":"16","author":"Saharinen","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.oret.2025.01.017_bib19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/35025215","article-title":"Vascular-specific growth factors and blood vessel formation","volume":"407","author":"Yancopoulos","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.oret.2025.01.017_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100111","article-title":"YOSEMITE and RHINE: phase 3 randomized clinical trials of faricimab for diabetic macular edema: study design and rationale","volume":"2","author":"Eter","year":"2022","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.oret.2025.01.017_bib21","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.017_bib22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2025.01.017_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40123-021-00342-5","article-title":"Importance of anatomical efficacy for disease control in neovascular AMD: an expert opinion","volume":"10","author":"Balaskas","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.oret.2025.01.017_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3928\/23258160-20221122-01","article-title":"The impact of residual retinal fluid following intravitreal anti-vascular endothelial growth factor therapy for diabetic macular edema and macular edema secondary to retinal vein occlusion: a systematic review","volume":"54","author":"Patil","year":"2023","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2025.01.017_bib25","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","article-title":"Guidelines on diabetic eye care: the International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings","volume":"125","author":"Wong","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.01.017_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/2474126419834711","article-title":"Evidence-based guidelines for management of diabetic macular edema","volume":"3","author":"Bakri","year":"2019","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.oret.2025.01.017_bib27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2025.01.017_bib28","series-title":"Ranibizumab for treating diabetic macular oedema: technology appraisal guidance","year":"2013"},{"key":"10.1016\/j.oret.2025.01.017_bib29","series-title":"Aflibercept for treating diabetic macular oedema: technology appraisal guidance","year":"2015"},{"key":"10.1016\/j.oret.2025.01.017_bib30","series-title":"Faricimab for treating diabetic macular oedema. technical appraisal guidance","year":"2022"},{"key":"10.1016\/j.oret.2025.01.017_bib31","doi-asserted-by":"crossref","first-page":"8154","DOI":"10.1167\/iovs.12-10290","article-title":"Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography","volume":"53","author":"Chalam","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2025.01.017_bib32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2307\/3001616","article-title":"Some methods for strengthening the common \u03c72 tests","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1016\/j.oret.2025.01.017_bib33","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.oret.2025.01.017_bib34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"10.1016\/j.oret.2025.01.017_bib35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s10384-023-00979-8","article-title":"Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial","volume":"67","author":"Shimura","year":"2023","journal-title":"Jpn J Ophthalmol"},{"issue":"suppl 1","key":"10.1016\/j.oret.2025.01.017_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41433-020-0961-6","article-title":"Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group","volume":"34","author":"Amoaku","year":"2020","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.01.017_bib37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcjo.2022.03.003","article-title":"Impact of retinal fluid in patients with diabetic macular edema treated with anti-VEGF in routine clinical practice","volume":"58","author":"Kalur","year":"2023","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.017_bib38","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41433-019-0522-z","article-title":"Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: a post hoc analysis of protocol I data","volume":"34","author":"Sadda","year":"2020","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.01.017_bib39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.survophthal.2022.11.008","article-title":"Persistent diabetic macular edema: definition, incidence, biomarkers, and treatment methods","volume":"68","author":"Sorour","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2025.01.017_bib40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41433-023-02637-2","article-title":"Exploring the role of retinal fluid as a biomarker for the management of diabetic macular oedema","volume":"38","author":"Khoramnia","year":"2024","journal-title":"Eye (Lond)"},{"issue":"suppl_1","key":"10.1016\/j.oret.2025.01.017_bib41","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2337\/db18-726-P","article-title":"Patient perspectives on the burden of type 2 diabetes mellitus treatment","volume":"67","author":"Yu-Isenberg","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.oret.2025.01.017_bib42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/PROM.S44694","article-title":"A systematic review of patient-reported measures of burden of treatment in three chronic diseases","volume":"4","author":"Eton","year":"2013","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.oret.2025.01.017_bib43","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/eye.2015.142","article-title":"Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose)","volume":"29","author":"Do","year":"2015","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.01.017_bib44","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2025.01.017_bib45","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/IAE.0000000000003441","article-title":"Intravitreal nesvacumab (antiangiopoietin 2) plus aflibercept in diabetic macular edema: phase 2 RUBY randomized trial","volume":"42","author":"Brown","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.01.017_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070459","article-title":"Angiopoietin-2 is critical for cytokine-induced vascular leakage","volume":"8","author":"Benest","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2025.01.017_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1192464","article-title":"Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia\/reperfusion","volume":"17","author":"Canonica","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.oret.2025.01.017_bib48","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s13300-022-01326-9","article-title":"The role of angiopoietins in neovascular diabetes-related retinal diseases","volume":"13","author":"Collazos-Alem\u00e1n","year":"2022","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.oret.2025.01.017_bib49","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1167\/iovs.10-6386","article-title":"A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy","volume":"52","author":"Rangasamy","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2025.01.017_bib50","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1001\/jamaophthalmol.2020.2457","article-title":"Quantification of fluid resolution and visual acuity gain in patients with diabetic macular edema using deep learning: a post hoc analysis of a randomized clinical trial","volume":"138","author":"Roberts","year":"2020","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025000491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025000491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:10:47Z","timestamp":1777633847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653025000491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2468653025000491"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2025.01.017","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE\/RHINE Trials in Diabetic Macular Edema","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2025.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00c2\u00a9 2025 Published by Elsevier Inc. on behalf of American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}